12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lenvatinib: Phase Ib/II data

Data from 78 evaluable patients with stage IV melanoma in the modified intent-to-treat (mITT) population of the Phase II portion of a Phase Ib/II trial showed that 20 mg oral lenvatinib plus dacarbazine met the primary endpoint of improving median PFS vs. dacarbazine alone (19.1 vs. 7 weeks, p=0.0033). In patients with wild-type BRAF V600 (n=37), lenvatinib plus dacarbazine led to a median PFS of 23.9...

Read the full 319 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >